Impact of maralixibat on cholestatic pruritus in young adults aged 16 years and older with Alagille syndrome

G. Hirschfield,D. Mogul,A. Soglian,M. Baek,P. Vig,B.M. Kamath

DOI: https://doi.org/10.1016/j.dld.2024.01.040

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Introduction Data in ALGS has primarily focused on pediatric patients, however adults with ALGS who survive with their native liver may require treatment for cholestasis and pruritus. Aim We report on the efficacy and safety of MRX, an IBAT inhibitor, in young adults aged ≥16 years with ALGS transitioning to adult care. Methods & Results Participants received ≥1 dose of MRX ≥16 years of age within the MRX ALGS clinical development program. Pruritus [ItchRO (Obs)] and serum bile acids (sBA) were assessed at Baseline, before and after 16 years, and at study end. 14 individuals were included; 11 began treatment at <16 years of age and 3 patients began MRX ≥16 years. Baseline mean (SE) pruritus score was 2.5 (0.21), and significantly decreased to 0.8 (delta = -1.7; p = 0.002); pruritus response was durable with no significant change before and after age 16 years (delta = -0.2; p = 0.2), or to end of therapy (delta = 0.2; p = 3) in individuals that started MRX <16 years old. Baseline mean sBA was 130 µmol/L, significantly decreased to 52 µmol/L (delta = -79; p = 0.03) prior to 16 years; no significant change before and after age 16 years (delta = -7; p = 0.3), or to end of therapy (delta = 3; p = 0.4) was observed. Three individuals that started MRX ≥16 years had improvements in pruritus from Baseline (delta = -2.8, -0.6, and -1.0). One patient had a large decrease in sBA (delta = -112 µmol/L) and two had small increases in sBA (delta = 8 and 11 µmol/L). MRX was generally well tolerated with the same safety profile previously reported. Conclusions MRX was effective, durable, and well tolerated in ALGS patients ≥16 years, providing critical data for patients who transition to adulthood while on therapy.

gastroenterology & hepatology